<DOC>
	<DOC>NCT01393626</DOC>
	<brief_summary>This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).</brief_summary>
	<brief_title>A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Male or female subjects between the ages of 18 and 75 years at screening (upper age limit will be 64 years in India and 65 years in the Netherlands). Subjects with clinical diagnosis of Crohn's disease for at least 6 months prior to screening. Subjects with active moderate to severe ileal, ileocolic, or colonic CD defined by a baseline score of Crohn's Disease Activity Index (CDAI) of 220 to 450 at baseline. Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC. Subjects diagnosed with Crohn's disease but without previous exposure to treatment (i.e., treatmentnaïve). Subjects receiving the following treatment for Crohn's disease: Azathioprine, 6mercaptopurine or methotrexate within 2 weeks prior to baseline. AntiTNFα therapy within 8 weeks prior to baseline. Interferon therapy within 8 weeks prior to baseline. Cyclosporine, mycophenolate, or tacrolimus within 4 weeks prior to baseline. Intravenous corticosteroids within 2 weeks prior to baseline.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>